<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg"/></p>
<p>在一次重大领导层变动中，西维斯（CVS Health）任命资深高管大卫·乔纳（David Joyner）为新 CEO，接替卡伦·林奇（Karen Lynch）。</p>
<p>这一决定是因为西维斯正面临着重大的利润困境，受到医疗成本上升和其零售药店消费下降的影响。</p>
<p>该消息是在周五发布的，此前西维斯股价今年已经下跌近 20%，在领导层变动披露后的盘前交易中暴跌 13%。</p>
<p>该公司一直在应对其保险部门 Aetna 的挑战，高于预期的医疗成本对盈利能力造成了压力。</p>
<p>今年 8 月，西维斯下调了全年利润预期，并透露计划在未来几年削减 20 亿美元的成本，以稳定其财务表现。</p>
<h2>西维斯股票：公司称医疗效益比为 95.2%</h2>
<p>在最新的声明中，西维斯为第三季度提供了指引，预计调整后的每股收益在 1.05 美元至 1.10 美元之间。</p>
<p>该公司还提到了预期的医疗效益比为 95.2%，由于其医疗保健部门持续面临成本压力，高于先前预期。投资者被告知不要依赖先前的盈利指引，考虑到公司医疗福利部门持续承受的压力。</p>
<p>西维斯计划于 11 月 6 日发布其第三季度财报，这是投资者期待更多了解公司财务方向的关键日期。</p>
<p>此次领导层变动是受到西维斯的主要股东 Glenview Capital 的不断施压而进行的，后者一直在倡导对公司进行重大改变。</p>
<p>上个月也有报道称，西维斯董事会正在与战略顾问合作，探讨各种选项，包括潜在分拆其保险和零售部门。</p>
<p>大卫·乔纳此前曾领导西维斯的药房服务，担任西维斯凯玛克（CVS Caremark）总裁，预计他将为 CEO 角色带来深厚的行业专业知识。</p>
<p>乔纳在 Aetna 的药品福利部门开始了他的职业生涯，并在西维斯内担任过多个高级领导职位。</p>
<p>他的任命被视为一项战略举措，旨在引领公司度过当前的挑战并释放未来价值。</p>
<p>董事长罗杰·法拉表示：“我们相信大卫对我们综合业务的深刻理解将使我们能够应对我们行业面临的挑战，并加速所需的运营改进。” 法拉将担任执行董事长。</p>
<p>卡伦·林奇辞去 CEO 职务后，也从公司董事会辞职。</p>
<p>乔纳将作为领导层过渡的一部分加入董事会。</p>
<p>在西维斯努力恢复投资者信心和提高盈利能力的同时，乔纳领导下的新领导层旨在引领公司度过这一关键的转型阶段。</p>
<p>文章来源：Invezz，西维斯股价下跌 13%，公司用大卫·乔纳取代 CEO 卡伦·林奇</p>

西维斯

<p>西维斯健康已任命大卫·乔纳（David Joyner）为首席执行官，接替卡伦·林奇（Karen Lynch），此举发生在公司利润严重下滑和股价下跌 13% 的背景下。这次领导层变动是在股价今年下跌近 20% 的情况下进行的，原因是医疗成本上升和消费者支出减少。西维斯已经削减了全年利润预期，并计划削减 10 亿美元的成本。乔纳此前担任西维斯 Caremark 的总裁，预计他将利用自己在行业中的专业知识来应对公司面临的挑战。西维斯将于 11 月 6 日发布第三季度财报，对投资者来说至关重要</p>

<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg"/></p>
<p>In a major leadership shift, CVS Health has named longtime executive David Joyner as its new CEO, replacing Karen Lynch.</p>
<div class="lb-trans"><p>在一次重大领导层变动中，西维斯（CVS Health）任命资深高管大卫·乔纳（David Joyner）为新 CEO，接替卡伦·林奇（Karen Lynch）。</p>
</div><p>The decision comes as CVS faces significant profit struggles, driven by rising medical costs and a drop in consumer spending at its retail pharmacies.</p>
<div class="lb-trans"><p>这一决定是因为西维斯正面临着重大的利润困境，受到医疗成本上升和其零售药店消费下降的影响。</p>
</div><p>The announcement, made on Friday, follows a nearly 20% decline in CVS shares this year, with the stock plunging 13% in premarket trading after the leadership change was disclosed.</p>
<div class="lb-trans"><p>该消息是在周五发布的，此前西维斯股价今年已经下跌近 20%，在领导层变动披露后的盘前交易中暴跌 13%。</p>
</div><p>The company has been grappling with challenges in its insurance unit, Aetna, where higher-than-expected medical costs have weighed on profitability.</p>
<div class="lb-trans"><p>该公司一直在应对其保险部门 Aetna 的挑战，高于预期的医疗成本对盈利能力造成了压力。</p>
</div><p>In August, CVS cut its full-year profit guidance and revealed plans to trim $2 billion in costs over the next few years to stabilize its financial performance.</p>
<div class="lb-trans"><p>今年 8 月，西维斯下调了全年利润预期，并透露计划在未来几年削减 20 亿美元的成本，以稳定其财务表现。</p>
</div><h2>CVS stock: company cites medical benefit ratio of 95.2%</h2>
<div class="lb-trans"><h2>西维斯股票：公司称医疗效益比为 95.2%</h2>
</div><p>In its latest statement, CVS provided guidance for the third quarter, forecasting adjusted earnings between $1.05 and $1.10 per share.</p>
<div class="lb-trans"><p>在最新的声明中，西维斯为第三季度提供了指引，预计调整后的每股收益在 1.05 美元至 1.10 美元之间。</p>
</div><p>The company also cited an expected medical benefit ratio of 95.2%—higher than previously anticipated due to ongoing cost pressures in its healthcare segment. Investors were cautioned not to rely on prior earnings guidance, given the continued strain on the company’s health benefits unit.</p>
<div class="lb-trans"><p>该公司还提到了预期的医疗效益比为 95.2%，由于其医疗保健部门持续面临成本压力，高于先前预期。投资者被告知不要依赖先前的盈利指引，考虑到公司医疗福利部门持续承受的压力。</p>
</div><p>CVS is scheduled to release its third-quarter earnings report on November 6, a key date for investors awaiting more clarity on the company’s financial direction.</p>
<div class="lb-trans"><p>西维斯计划于 11 月 6 日发布其第三季度财报，这是投资者期待更多了解公司财务方向的关键日期。</p>
</div><p>The leadership change follows growing pressure from Glenview Capital, a major CVS shareholder, which has been advocating for significant changes at the company.</p>
<div class="lb-trans"><p>此次领导层变动是受到西维斯的主要股东 Glenview Capital 的不断施压而进行的，后者一直在倡导对公司进行重大改变。</p>
</div><p>Reports also surfaced last month that CVS’s board was working with strategic advisors to explore various options, including a potential breakup of its insurance and retail divisions.</p>
<div class="lb-trans"><p>上个月也有报道称，西维斯董事会正在与战略顾问合作，探讨各种选项，包括潜在分拆其保险和零售部门。</p>
</div><p>David Joyner, who previously led CVS’s pharmacy services as president of CVS Caremark, is expected to bring deep industry expertise to the CEO role.</p>
<div class="lb-trans"><p>大卫·乔纳此前曾领导西维斯的药房服务，担任西维斯凯玛克（CVS Caremark）总裁，预计他将为 CEO 角色带来深厚的行业专业知识。</p>
</div><p>Joyner started his career at Aetna in pharmacy benefits and has held several senior leadership positions within CVS.</p>
<div class="lb-trans"><p>乔纳在 Aetna 的药品福利部门开始了他的职业生涯，并在西维斯内担任过多个高级领导职位。</p>
</div><p>His appointment is seen as a strategic move to navigate the company through its current challenges and unlock future value.</p>
<div class="lb-trans"><p>他的任命被视为一项战略举措，旨在引领公司度过当前的挑战并释放未来价值。</p>
</div><p>“We believe David’s deep understanding of our integrated business will allow us to tackle the challenges our industry faces and accelerate the operational improvements needed,” said Chairman Roger Farah, who will now assume the role of executive chairman.</p>
<div class="lb-trans"><p>董事长罗杰·法拉表示：“我们相信大卫对我们综合业务的深刻理解将使我们能够应对我们行业面临的挑战，并加速所需的运营改进。” 法拉将担任执行董事长。</p>
</div><p>Karen Lynch, who stepped down from her position as CEO, also resigned from the company’s board.</p>
<div class="lb-trans"><p>卡伦·林奇辞去 CEO 职务后，也从公司董事会辞职。</p>
</div><p>Joyner will now take a seat on the board as part of the leadership transition.</p>
<div class="lb-trans"><p>乔纳将作为领导层过渡的一部分加入董事会。</p>
</div><p>As CVS works to restore investor confidence and improve profitability, the new leadership under Joyner aims to steer the company through this critical phase of transformation.</p>
<div class="lb-trans"><p>在西维斯努力恢复投资者信心和提高盈利能力的同时，乔纳领导下的新领导层旨在引领公司度过这一关键的转型阶段。</p>
</div><p>The post CVS stock drops 13% as company replaces CEO Karen Lynch with David Joyner appeared first on Invezz</p>
<div class="lb-trans"><p>文章来源：Invezz，西维斯股价下跌 13%，公司用大卫·乔纳取代 CEO 卡伦·林奇</p>
</div>

西维斯股价下跌 13%，公司将 CEO Karen Lynch 替换为 David Joyner